Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
Portfolio Pulse from Benzinga Insights
In the last three months, 4 analysts have updated their ratings on Beam Therapeutics (NASDAQ:BEAM), showing a shift towards a more positive outlook with an average 12-month price target of $43.5, reflecting a 43.42% increase from the previous average of $30.33. The company has shown significant financial growth, with a revenue increase of 1478.04% as of December 31, 2023, and outperforms industry averages in net margin, ROE, and ROA.
March 27, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beam Therapeutics has received updated positive ratings from analysts, with an increased average 12-month price target of $43.5. The company's financial performance is strong, with significant revenue growth and superior industry metrics.
The positive shift in analyst ratings and the substantial increase in the average price target reflect growing confidence in Beam Therapeutics' market position and financial health. The company's exceptional revenue growth and performance metrics such as net margin, ROE, and ROA, significantly above industry averages, support a bullish outlook for the stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100